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1. Introduction 
Disturbances in immune tolerance provoke autoimmune aggression, i.e., a specific immune 
response to auto-Ags with subsequent development of an autoimmune syndrome or an 
autoimmune disease (Suchkov et al., 2007). 
A crucial role in formation of autoimmune syndromes and progression of autoimmune 
diseases is played by inborn (in the first place, HLA-associated) predisposition coupled with 
impaired immune responsiveness of the invaded organism. Noteworthy, initiation and 
progression of autoaggressive reactions cannot be triggered without preliminary activation 
of signaling reaction cascades, which include:  
i. polyclonal activation of autoreactive cytotoxic T lymphocytes (CTL) by super-Ag 
(multimolecular protein complexes composed of microbial Ags, Ags and/or haptens of 
the carrier or intermediary drug-related metabolites) demonstrating broad spectrum of 
epitopes; 
ii. release of sequestered or intramolecular (cryptic) autoepitopes after the tissue damage 
or organ injures during the inflammatory process; 
iii. anti-idiotypic Ab formation that can damage own tissue and promote autoagression; 
iv. effect of mimicking epitopes (microbial Ags cross-reacting with autoepitopes of human 
tissues and organs). 
Of particular interest in this respect is so-called molecular mimicry. Its biological mechanism 
is based on cross-reactivity, i.e., ability of the infected organism to cross-react, by virtue of 
structural homology between its auto-Ags and microbial Ags, with the microbial antigen 
thereby triggering miscellaneous immune reactions. Under these conditions, the role of 
autoaggressors is played simultaneously by two different groups of Ags, namely, mimicking 
Ags of the microbial pathogen and patient’s own autoAgs. Their interactions form the 
clinical picture of the postinfectious autoimmune syndrome (PIFA), one of main clinical 
variants of syndromeal immune pathology (Paltsev et al., 2009a).  
Today, the key role of the immune system in the pathogenesis of chronically relapsing 
infectious diseases (CRID) leaves no doubt. Their clinical course is controlled by an immense 
variety of factors and their combinations among which the immunologic syndrome (IS) 
reflecting the origin and severity of disturbances in immune homeostasis occupies a special 
niche. The concept of IS is not new in principle and is widely met in the current literature. 
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However, the term ”clinico-immunological syndrome” (CIS) is far less explicit and needs to be 
supplemented with a pathogenetically rationalized, clinically significant formulaic 
definition encompassing the tremendous body of evidence accumulated thus far in the 
modern literature (Paltsev et al., 2009b) (Fig. 1).  
 
 
Fig. 1. Clinical and immunological criteria of PIFSI 
PIFSI – postinfectious secondary immunodeficiency syndrome. 
In this section, we shall consider one of the most important clinical aspects of CIS, viz., 
postinfectious CIS (PICIS) whose role for practitioners in clinical medicine can hardly be 
overestimated. PICIS being a form of secondary (syndromal) immune pathology associated 
with the underlying (infectious) disease is provoked by a variety of factors including 
infectious pathogens of various etiology, clinical progression and complication of the 
disease proper, or inadequately applied antimicrobial therapy. The most common forms of 
this syndrome are as follows:  
i. postinfectious secondary immunodeficiency syndrome (PIFSI); 
ii. (ii) postinfectious autoimmune syndrome (PIFA); 
iii. autoimmune syndrome coupled with postinfectious secondary immunodeficiency 
(PIFASID) (Suchkov et al., 2004). 
Predisposition to one or another form of syndromeal immune pathology depends on a great 
number of genetically determined factors, which play a key role in the formation of patient’s 
own immune resources. Its functional activity is controlled by coordinated functioning of 
innate and adaptive immune mechanisms; however, their role in the development and 
chronization of infectious processes is still open to question, which strongly impedes the 
construction of state-of-art immunopathogenetic models (Fig. 2). 
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Fig. 2. The innate and adaptive branches of immunity. 
In this context, analysis of major immunopathologic manifestations in patients with PICIS-
related chronically relapsing infectious diseases and construction of basic algorithms for 
state-of-art immunogenetic diagnostic protocols becomes a prime target for clinical 
medicine. 
Human immune system is a complex physiological mechanism whereby the human 
organism protects itself from exogenous etiopathogenic attacks. Its functional activity is 
provided by two types of protective immune mechanisms, one of which is specific and the 
other one is nonspecific. The main outcome of the immune response to etiopathogenic attacks 
is formation of two populations of regulatory Т helper cells (Th cells). The Th population is 
further subdivided into Th1 cells responsible for activation of effector links of cell-mediated 
immunity (macrophages and cytotoxic T lymphocytes/CTL) and Th2 cells exerting control 
over antibody (AB) production (McGuirk & Mills, 2002) (Fig. 3). 
However, the key factor in determining a particular type of the immune response and, 
correspondingly, a particular form of CIS, is localization (extracellular or intracellular) of the 
etiopathogen (Fig. 4). 
The latter circumstance is of particular importance from both pathogenetic and  clinical 
points of view, since the majority of currently known pathogenic microorganisms can 
escape from immune control and, in doing so, change the scenario of genetically 
programmed immune  responsiveness thereby provoking unpredictable complications for 
the patient and hindering physician’s attempts to implement adequate treatment strategies 
(Azikury, 1985; Aitpaev & Seisembekov, 1987). 
Two major disturbances in immune responsiveness are presently recognized as causal 
factors in chronization of infectious diseases and formation of PICIS: 
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Note: In the presence of IL-4, precursor Тh0 cells are transformed into Тh2 cells whose main function 
consists in activation of humoral immunity and production of definite classes of cytokins, viz., IL-3, IL-
4, IL-5, IL-6, IL-10, IL-13, TNF, etc. Under the action of IL-12, Тh0 precursors are transformed into Тh2 
cells stimulating the production of other cytokin populations, e.g., IL-2, IL-3, IFN –Ǆ, TNF-ǂ, TNF-ǃ, 
etc., able to activate cell-mediated immune responses. Other Th1/Th2 classes are represented by natural 
killer cells (NK cells), helper Т cells (Th cells), granulocytic macrophageal colony-stimulating factors 
(GM-CSF), interferon (IFN), interleukin (IL), macrophages (MØ) and tumor necrosis factor (TNF). 
Fig. 3. The pathways of formation of Th1/Th2 lymphocytes. 
i. deficiency of effector links of immunity with predominant involvement of the Т link (as 
in the case of isolated forms of PIFSI); 
ii. disbalance of intercellular immunoregulatory mechanisms responsible for the 
formation of associated forms of syndromeal immune pathologies, e.g., PIFA and 
PIFASID). 
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Note: PMNL and NK are polymorphonuclear leukocytes and natural  killer  cells, respectively. 
Fig. 4. The contribution of the innate and adaptive branches of immunity to control over 
intra- and extracellular infections. 
2. Clinical manifestations of PICIS in the framework of clinical models of 
CRID 
As targets for our investigation, we chose three classical models of CRID, namely, 
intracranial infectious inflammatory pathologies (ICIIP), chronic pyelonephrites (CPN) and 
myocardites (М). All these pathologies have one common feature (i.e., association with a 
concrete organ or a tissue), but differ from one another both topically and pathogenetically. 
Although the panel of immunologic disturbances varies substantially depending on the 
clinical form of PICIS, immune statuses of patients and clinical manifestations of the 
diseases are very similar (Antonov & Tsinzerling, 2001; Borisov, 2000; Kukhtevich et al., 
1997; Morozov, 2001; Paukov, 1996). 
2.1 Immunopathological factors as biomarkers and biopredictors of chronization of 
infectious diseases 
2.1.1 Inflammation mediators as PICIS-related factors 
Emergence and accumulation, in patient’s blood, of inflammation markers whose 
concentration reaches the highest level in patients with PIFA and degresses in the direction 
from PIFASID to PIFSI are the most common markers of chronization of infectious diseases 
and formation of syndromeal immune pathologies (Mazo et al., 2007; Litvinov et al., 2008; 
Zhmurov et al., 2000; Rumyantsev & Goncharova, 2000). 
2.1.2 Abnormalities in the innate branch of immunity as a PICIS-related factor 
Miscellaneous shifts in the innate branch of immunity play a no less important role in 
chronization of infectious diseases. Thus, pronounced suppression of innate immune 
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mechanisms is a salient feature of PIFSI, while PIFA and PIFASID are distinguished for 
disproportions in individual links of innate immunity and/or disbalance in the functional 
activity of its specific mechanisms (Bauer et al., 2001; Bingen-Bidois et al., 2002; Blackwell et 
al., 1987; Carballido et al., 2003; Dantzer & Wollman, 2003). 
Complement deficiency. In patients with PIFA and PIFASID, outbursts of activity in the ǿ5 
and ǿ5а components of the complement are usually observed against the background of 
stable operation of the majority of other links of the immune system (PIFA)  or pronounced 
disproportions between them (PIFASID). 
Deficiency of phagocytosis and cytotoxicity mechanisms. To factors responsible for 
chronization of infectious diseases, one may relate oppositely directed changes in 
phagocytosis and cytotoxicity parameters.  In PIFSI, both mechanisms are strongly 
suppressed, while in PIFA and PIFASID relative stability of certain components of both 
systems is concomitant with disproportions in other components. 
Deficiency of dendritic cells. Dendritic cells (DCs) are among the most essential regulatory 
factors in the innate branch of immunity. In patients with PIFSI, the specific contribution of 
these cells is rather small, while in case of PIFASID and PIFA DCs play a prominent role and 
show a tendency for activation (Sanaev et al., 2008; Cherepakhina et al., 2009). 
2.1.3 Abnormalities in the adaptive branch of immunity as a PICIS-related factor 
Deficiency of Т cell-mediated immunity. Among other disturbances in the adaptive branch 
of immunity, special attention should be given to differently directed changes in Т cell-
mediated immunity. PIFSI, for example, is characterized by enhanced suppression of Т cell 
functions resulting from disproportions in immunoregulatory components and massive 
apoptosis of Т cells. In contrast, activation of Т cell-mediated immunity is critical for PIFA 
and PIFASID, being more pronounced for the former and less pronounced for the latter. 
Deficiency of humoral immunity. Suppression of humoral immunity is a characteristic 
feature of PIFSI, while PIFA and PIFASID are associated with its activation. The activating 
effect of quantitative and qualitative (functional) mechanisms of humoral immunity is 
especially apparent in PIFA, while in patients with PIFASID this effect is far less expressed. 
Disproportions in the cytokin spectrum of the blood. PIFSI is associated with significant 
reduction of the population of antiinflammatory cytokins, while in PIFA this population is 
predominant. PIFASID is characterized by general disproportions in the cytokin spectrum at 
large (Cherepakhina et al., 2010a). 
3. PICIS and its main clinical forms 
3.1 PIFSI 
The main clinical manifestations of PIFSI are related to disturbances in antimicrobial 
protective mechanisms due to deficiency of the innate branch of immunity and development 
of secondary immune pathologies in the adaptive branch of immunity. The latter manifest 
themselves as chronically relapsing infectious diseases of bacterial or mixed origin 
(Shogenov et al., 2006). 
3.2 PIFA 
During induction and progression of CRID, some autoreactive CTL cross-reacting with 
microbial antigens (Ags) in the paradigm of the infectious process undergo activation by 
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hazardous factors including molecular mimicry (Khitrov et al., 2007a; Fujinami et al., 2006; 
Rose & Mackay, 2000; Benoist & Mathis, 2001). Its consequences are especially apparent 
during recognition of determinant autoAgs by Т cells and subsequent formation of the PIFA 
syndrome (Fig. 5). The latter attack any target organ or tissue of the infected organism by a 
rocket mechanism.  The risk of PIFA development increases dramatically with increasing 
incidence of infectious diseases and the panel of infecting pathogens (mixed infections). 
 
 
Note: The primary infectious (microbial) pathogen triggers a  postinfectious autoimmune syndrome 
(PIFA) through activation of two different mechanisms: (i) depletion of intrinsic (antigenic) molecular 
mimicry pools of cross-reacting (mimicking) antigenic determinants of the infecting pathogen (red 
arrows); (b) generation, by the infectious pathogen, of antigen-nonspecific signals (blue arrows) able to 
induce inflammation and thus enhance  immune  responsiveness (so-called adjuvant effect). 
Fig. 5. A schematic representation of the postinfectious autoimmune syndrome (PIFA). 
There exist at least three different interpretations for the relatedness of the infectious process 
to the risk of PIFA in response to activation of autoreactive clones of Т and В lymphocytes, 
namely: (i) stimulation by microbial superAgs; (ii) secretion of cryptic (intramolecular) 
autoAg determinants in response to cell damage induced by persisting infections and  (iii) 
molecular mimicry. These pathogenetic mechanisms are not mutually exclusive and play a 
crucial role in definite (as a rule, early) steps of PIFA-related CRID. The main triggering 
factors in the PIFA initiation step are: (i) antigenic activity of the microbial pathogen and (ii) 
tropism of the microbial pathogen towards definite cell populations, organs and tissues as 
targets for its cytopathic effect (Vturin et al., 1994; Manges et al., 2004). 
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Contrary to PIFSI, all classes of antimicrobial ABs (antibacterial, antiviral, antiparasitic, etc.) 
are morbid in PIFA. Although in the majority of patients the incidence and titers of 
antibacterial and antiviral ABs are more or less identical, in certain forms of CRID (e.g., CPN 
or М) antiparasitic ABs are detected in highest titers, while in patients with other 
pathologies (e.g., ICIIP) they are absent. These findings can be attributed to clinical 
manifestations of the underlying diseases rather than to inadequate functioning of 
triggering mechanisms of PIFA) (Cherepakhina et al., 2010b). 
Indeed, autoaggression provoked by insufficient coordination between two branches of 
immunity and hyperfunction of its adaptive branch is a dominant feature of PIFA. Its 
unique feature is a vast repertoire of antiorganic and antitissue autoABs responsible for 
multiseropositivity and specific autoimmune inflammation markers, e.g., anti-B7-HI autoABs) 
(Khitrov et al., 2007). 
By illustration, antimyelin and antineuronal autoABs are usually associated with ICIIP.  
Patients with CPN contain predominantly anti-THG autoABs as highly specific markers of 
autoimmune inflammation in renal tissue, while the presence of anti-КМ autoABs indicates 
AIM (Miller et al., 1970). 
To the most informative models of PIFA one may relate autoimmune myocarditis (AIM), 
autoimmune encephalomyelitis (AEM), ICIIP, rheumatoid arthritis (ǾА), autoimmune 
hepatitis (AIHe), autoimmune colienteritis (AICE), autoimmune pancreatitis (AIPCT), 
autoimmune gastritis (AIGa), autoimmune (streptococcal) glomerulonephritis (AGN), 
CPN, etc. 
Autoimmune myocarditis (AIM) usually develops in genetically predisposed individuals 
infected with the Coxsackievirus-3 virus (CVB3) and is one of the most typical 
manifestations of molecular mimicry. The presence, in circulating blood, of cardiomyosin-
autoreactive cytotoxic Т lymphocytes (КМ-autoreactive CTL) and anti-КМ autoABs is 
prerequisite to AIM development. Their interactions in patients with PIFA or PIFASID 
initiate myocardial lesions in response to enhanced secretion of sequestered autoAgs 
(Shogenov et al., 2010) (Fig. 6).  
In type I diabetes mellitus (DM I), insulitis develops in genetically predisposed individuals 
at the earliest (preclinical) stages of the disease (as a rule, against the background of 
infection with the Coxsackie-4 virus (CVB4)), and is further transformed into PIFA. This 
pathological process is mediated by autoreactive CTL and autoABs against islet autoAgs.  
Their coordinated functioning initiates the destruction (direct or indirect) of beta cells, e.g., 
through secretion of cytokins, generation of free radicals or apoptosis of beta cells, 
eventually resulting in PIFA or PIFASID. 
The main causal factors in initiation of chronically relapsing autoimmune colienteritis 
(AICE) are mimicking AGs of microbial or dietary origin. These AGs are localized in the 
intestinal lumen where they activate immune cells of intestinal mucosa.  Having penetrated 
into these cells, AGs begin to interact with tissue immunocytes (most frequently, with 
lymphocytes and DCs) thereby triggering adaptive immune responses. Innate immune 
resources also become activated under the stimulating effect of microbial products due to 
activation of specific surface receptors of intestinal epithelium. This reaction cascade 
stimulates the secretion of numerous cytokins and chemokins able to activate immunocytes  
of intestinal mucosa. Activation of antigen-presenting cells (APC) (e.g., DCs) initiate 
enhanced production of Th1 cells (Crohn’s disease) or atypical Th2 cells (ulcerative colitis). 
In addition to major cytokins  stimulating the activity of Th1 cells (IL-12, IL-18, etc.), 
activated macrophages give rise to a great diversity of antiinflammatory cytokins (IL-1, IL-6, 
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Note: AB – antibody; CTL – cytotoxic Т lymphocyte; IFN - interferon; IL – interleukin; NK – natural 
killer cell; DCМǽ – dilated cardiomyopathy. 
Fig. 6. Initiation and progression of myocarditis 
TNF alpha, etc.) endowed with an ability to stimulate the activity of different cell 
populations (including endothelial cells) in inflammation foci by promoting enhanced 
migration of lymphocytes, fibroblasts and epithelial cells from the vascular network to 
inflammation niduses, which significantly deteriorates the clinical picture of autoimmune 
nidal inflammation (Khaitov & Pinegin, 2000; Bach, 2005). 
3.3 PIFASID 
A salient feature of this syndrome is equal contribution of associated abnormalities to both 
branches of immunity. Its clinical picture is distinguished for mixed-type 
immunopathology, viz., autoimmune syndrome coupled with immunodeficiency and 
concurrent deterioration of antiinfectious protection.  
4. Associative correlation between clinical manifestations of PICIS and CRID 
The associativity between microbial infection and various immunopathological states with 
PICIS can be correlative or causal. In patients with CRID, syndromal forms of immune 
pathologies depend critically on the stage of the inflammatory process occurring in target 
organs or tissues and general chronization of the disease (Sanaev et al., 2007). 
For example, early stages of CRID are concomitant with PIFSI (› 50%), whereas the 
contribution of PIFA and PIFASID does not exceed 20%. At the subsequent stages, the 
clinical picture is different, viz., the contribution of the autoimmune syndrome increases 
dramatically (to 50% at the intermediate stages (PIFA) and to 60% at the final stage 
(PIFASID). 
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The correlation between the stage of CRID and the form of PICIS is also characterized by the 
involvement of an additional (third) component, viz., clinical form or variant of CRID. Here 
are several analytical examples related to:  
1. clinical form of CRID. In patients with primary pyelonephritis (PPNP) and infectious 
myocarditis (IM), PIFSI is detected in 75% of cases, whereas in patients with secondary 
pyelonephrites (SPNP) and AIM the contribution of PIFSI is notably decreased (to 25%) 
giving way to autoaggression (the contribution of PIFA and PIFASID increases to 60% 
and 85%, respectively); 
2. stage of CRID. At early stages (< 3 months for CPN and < 1 month for myocarditis (М)), 
PIFSI is detected in 40% of cases; however, at later stages of CRID its share decreases 
appreciably, while that of autoimmune syndromes increases in contrast; 
3. rate of progression and chronization of CRID. In patients with relapsing or rapidly 
progressing CRID (e.g., ICIIP or AIM), the contribution of PIFSI does not exceed 32-
36%, while the share of autoimmune syndromes reaches 80-100%. In such patients, 
persistent forms of meningoencephalitis (e.g., ICIIP) or AIM associated with myocardial 
dystrophies are predominant. 
These findings suggest that PIFSI is not only the outcome of the infectious process, but also 
represents a factor responsible for its lingering and chronically relapsing course. Further 
progression and chronization of CRID are controlled by postinfectious autoaggression 
factors, such as PIFA and PIFASID. 
5. Clinico-immunological criteria of PICIS and state-of-art immunogenetic 
diagnostic algorithms 
So far, there is no unique set of criteria for adequate assessment of immune statuses of 
patients with different forms of PICIS, most probably, due to immense diversity of clinical 
manifestations of syndromal immunopathologies and factors responsible for their 
emergence. Moreover, existing laboratory protocols for assessing immune statuses are 
nonspecific and do not include specific analyses of microbial pathogens (Vinnitskij, 2002; 
Kolesnikov et al., 2001; Cherepakhina et al., 2010c). 
With this in mind and in order to procure adequate evaluation of many syndromal immune 
pathologies, we developed a series of clinical and immunologic tests and criteria for more 
precise diagnosis of PICIS. The criteria for constructing immunogram charts include: 
i. screening of abnormalities in the innate branch of immunity (selective markers of 
phagocytosis,  natural cytotoxicity (NCT), basic functional parameters of DC- and Ag-
presenting cells (APC)   and complement components (if necessary); 
ii. screening of abnormalities in the adaptive branch of immunity (selective markers of effector 
or regulatory links of the immune system, serotyping of  blood elements for anti-
organic and anti-tissue autoABs concurrently with identification  of Abs against 
mimicking Ag determinants of  infecting pathogens). 
The main criteria in the etiotropic diagnosis step (design of microbial landscape  maps) 
include: 
i. identification and localization of  microbial gene pools; 
ii. serological profiles of antimicrobial ABs. 
The novel diagnostic ideology is based on a combination of two categories of investigations: 
i. pathogenetically oriented diagnosis of PICIS and (ii) etiotropic diagnosis of microbial 
pathogens as the main causal factors of PICIS. 
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The most efficient technological strategies will be based on: 
i. at the immunodiagnostics stage (cytofluorimetric analysis of  processing and presentation 
of AGs on the surface of APC, monitoring of antiorganic and antitissue autoAB pools, 
analysis of metabolic profiles of individual cells, etc.); 
ii. etiotropic diagnostics (combination of conventional techniques for culturing microbial 
cells with advanced molecular diagnostics strategies based on sequencing of microbial 
genomes, screening of biological fluids and tissues for antimicrobial ABs, etc.). 
6. Conclusion 
Morbidity from infectious pathologies (e.g., CRID), in the first place, those provoked by 
viruses, conditionally pathogenic (“opportunistic”) microflora  and/or pathogens endowed 
with atypical properties including muiltiple resistance to antibacterial drugs, is steadily 
increasing. Among other things, CRID-affected individuals are characterized by lowering 
general immune responsiveness concurrent with unusual forms of immune responses to the 
clinical course of the infectious pathology. Studies in this field including our own 
investigations established that PICIS is one of the most important clinical manifestations of 
CRID, since it determines, in many features, the progression and chronization of underlying 
pathologies and their possible complications. The monosyndromal dominant form of PICIS in 
patients with CRID is PIFSI. However, more than 30% of CRID patients suffer from more 
specific forms of PICIS concomitant with autoimmune aggression (PIFA) or from combined 
immunopathological forms (e.g., PIFASID). 
Clinical forms of PICIS and, correspondingly, immunologic disturbances in patients with 
CRID correlate associatively with the clinical picture of the disease. It is not excluded that 
chronization of infectious inflammatory processes involves a general sequence of 
pathogenetically important factors, which differ in inner architechtonics of each of PICIS 
variants and thus demonstrate their high criterial significance. 
Future progress in clinical immunology and immune biotechnology may open up fresh 
opportunities for introduction into routine clinical practice of advanced protocols for 
immunogenetic diagnostics of PICIS-related infectious diseases and design of state-of-art 
treatment-and-rehabilitation protocols based on the use of the most advanced 
immunogenetic tools and strategies. 
7. References 
Suchkov S.V.; Shogenov Z.S. & Khitrov A.N. (2007). Postinfectious autoimmune syndrome: 
features of pathogenesis and modern protocols of clinical immunogenodiagnostics. 
Therapeutic Archives. Vol.79, No.4, (April 2007), pp. 71-76, ISSN 0040-3660 
Paltsev M.A.; Cherepakhina N.E. & Suchkov S.V. (2009). Postinfectious clinical immunologic 
syndrome: foundations of etiopathogenesis and strategy of 
immunogenodiagnostics. Bulletin of the Russian Academy of Medical Sciences. Vol.10, 
(October, 2009), pp. 25-31, ISSN 0869-6047 
Paltsev M.A. Clinical and immune-mediated syndrome (CAIMS) in clinical practice: features 
and strategies in immune and molecular diagnostics. (2009). New Horizons in 
Allergy, Asthma & Immunology, pp. 177-181, ISBN 978-88-7587-505-3, Dubai, UAE, 
April 24-27, 2009  
www.intechopen.com
 Autoimmune Disorders – Pathogenetic Aspects 
 
138 
Suchkov S.V.; Blagoveschenskij S.V. & Vinnitskij L.I. (2004). Modern aspects of 
immunopathogenesis and immunocorrection in patients with intracranial 
infectious inflammatory diseases. Allergology and Immunology. Vol.5, No.2, (2004), 
pp. 323-330, ISSN 1562-3637 
McGuirk P. & Mills K.H. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 
paradigm in immunity to infectious diseases. (2002). Trends in Immunology. Vol.23, 
No.9, (September 2002), pp. 450-455, ISSN 1471-4906 
Azikury O.I. Cellular and humoral immunity at pyelonephritis. (1985). Urology and 
Nephrology. Vol.2, (March 1985), pp. 10-11, ISSN 0042-1154 
Aitpaev B. K. & Seisembekov T.Z. (1987). Cellular and humoral factors of nonspecific 
resistance and immunologic reactivity at chronic pyelonephritis. Therapeutic 
Archives. Vol.8, (August 1987), pp. 59-63, ISSN 0040-3660 
Antonov V.P. & Tsinzerling V.A. Contemporary status of the problem of chronic and slow 
neuroinfections. (2001). Archieves of Pathology. Vol.63(1), (January 2001), pp. 47-51, 
ISSN 0004-1955 
Borisov I.A.  Pyelonephritis. (2000). In: Nephrology, Tareeva I.E. (Ed.), pp. 383-399, Medicine, 
ISBN 5-225-04195-7, Moscow, Russia  
Kukhtevich A.V.; Gordovskaya N.B. & Kozlovskaya N.L. Pyelonephritis. Russian Medical 
Journal. Vol.5, No.23, (December 1997), pp. 54-62, ISSN 0869-7760 
Morozov A.V. Chronic infection of urinary tract (pathogenesis, diagnostic and treatment 
principles). Russian Medical Journal.  Vol.9, No.23, (December 2001), pp. 1074-1077, 
ISSN 0869-7760 
Paukov V.S. Immunology and morphology of chronic inflammation. Achieves of Pathology. 
Vol.58(1), (January 1996), pp. 28-33, ISSN 0869-7760 
Mazo E.B.; Vinnitskij L.I. & Litvinov V.A. (2007). Chronic pyelonephritis: features of 
immunopathogenesis and its’ clinical and diagnostical values. Therapeutic Archives.  
Vol.79(1), (January 2007), pp. 85-89, ISSN 0040-3660 
Litvinov V.A.; Cherepakhina N.E. & Suchkov S.V. (2008). Chronic pyelonephritis: features of 
immunopathogenesis and principles of clinical immunogenetic diagnostics. 
Physician. Vol.1, (January 2008), pp. 12-17, ISSN 0236-3054 
Zhmurov V.A.; Oskolkov V.A. & Malishevskij M.V. (2000). Correlation between 
immunogenetic markers and metabolic processes at chronic pyelonephritis. 
Urology. Vol.3, (2000), pp. 9-13, ISSN 0042-1154 
Rumyantsev A.S. & Goncharova I.S. Etiology and pathogenesis of pyelonephritis. 
Nephrology. Vol.4, No.3, (2000), pp. 40-52, ISSN 1561-6274 
Bauer J.; Rauschka H. & Lassmann H.  Inflammation in the nervous system: the human 
perspective. Glia, Vol.36, No.2, (November 2001), pp. 235-243, ISSN 1098-1136 
Bingen-Bidois M.; Clermont O. & Bonacorsi S.  Phylogenetic analysis and prevalence of 
urosepsis strains of Escherichia coli bearing pathogenicity island-like domains. 
Infect Immun. Vol. 70, No.6, (June 2002), pp. 3216-3226, ISSN 1098-5522 
Blackwell C.C.; May S.J. & Brettle R.P. Secretor state and immunoglobulin levels among 
women with recurrent urinary tract infections. J Clin Lab Immunol. Vol.22, No.3, 
(1987), pp. 133-137, ISSN 0141-2760 
Carballido J.A.; Alvarez-Mon M. & Olivier C.  Inflammatory pathology in urology. 
Standardization. Actas Urol Esp. Vol.27, No.3, (March 2003), pp. 173-179, ISSN 0210-
4806 
www.intechopen.com
 Postinfectious Autoimmune Syndrome as a Key Factor in Chronization of the Infectious Disease 
 
139 
Dantzer R. & Wollman E.E.  Relationships between the brain and the immune system. J Soc 
Biol. Vol.197, No.2, (2003), pp. 81-88, ISSN 0037-766X 
Sanaev A.O.; Kachkov I.A. & Vinnitskij L.I. (2008). Immunomonitoring and 
immunorehabilitation in case of intracranial infectious inflammatory diseases. 
Russian Journal of Immunology. Vol.2(11), No.1, (2008), pp. 78-82, ISSN 1028-7221 
Cherepakhina N.E.; Shogenov Z.S. & Elbeik T. (2009). Postinfectious clinical-and-
immunologic syndrome and its place in clinical practice. Therapeutic Archives. 
Vol.81(1), No.12, (December 2009), pp. 71-78, ISSN 0040-3660 
Cherepakhina N.E.; Tabaksoeva D.A. & Suchkov S.V. (2010). Associative relation of 
microbial factor and postinfectious clinical-and-immunologic syndrome in case of 
chronic relapsing diseases. Clinical Microbiology and Antimicrobial Chemotherapy. 
Vol.12, No.2, suppl.1, (2010), p. 54, ISSN 1684-4386 
Shogenov Z.S.; Cherepakhina N.E. & Suchkov S.V. (2006). Immunogenetic diagnostics  and 
postinfectious immunodeficiency syndrome in physicians’ practice. Clinical 
Laboratory Diagnostics. Vol.11, (November 2006), pp. 36-43, ISSN 0869-2084 
Khitrov A.N.; Shogenov Z.S. & Suchkov S.V. (2007). Molecular mimicry phenomenon and 
its place in postinfectious autoimmune syndrome (PIFA) pathogenesis. Molecular 
Medicine. Vol.4, (2007), pp. 24-32, ISSN 1728-2918  
Fujinami R.S.; von Herrath M.G. & Christen U. Molecular mimicry, bystander activation, or 
viral persistence: infections and autoimmune disease. Clin. Microbiol. Rev. Vol.19, 
No.1, (January 2006), pp. 80-94, ISSN 0893-8512 
Rose N.R. & Mackay I.R.  Molecular mimicry: a critical look at exemplary instances in 
human diseases . Cell Mol. Life Sci. Vol.57, No.4 (April 2000), pp. 542-551, ISSN 
1420-682X 
Benoist C. & Mathis D.  Autoimmunity provoked by infection: how good is the case for T 
cell epitope mimicry?  Nat. Immunol. Vol.2, No.9, (September 2001), pp. 797-801, 
ISSN 1529-2908 
Vturin B.V.; Delektorskij V.V. & Kovalchuk V.K. Pathogenic mechanisms of bacteria at 
different infections. (1994). Archives of pathology. Vol.56, No.5, (September 1994), pp. 
10-15, ISSN 0004-1955 
Manges A.R.; Dietrich P.S. & Riley L.W. Multidrug-resistant Escherichia coli clonal groups 
causing community-acquired pyelonephritis. Clin Infect Dis. Vol.38, No.3, (February 
2004), pp. 329-334, ISSN 0934-9723 
Cherepakhina N.E.; Maksimenko D.M. & Suchkov S.V. (2010). Microbial landscape and its 
value for the modern model of immunopathogenesis of chronic relapsing infectious 
diseases. Proceedings of the III World asthma & COPD forum and World forum of 
pediatrics, pp. 99-102, ISBN 978-88-7587-558-9, Dubai, UAE, April 24-27, 2010 
Khitrov A.N.; Shogenov Z.S. & Tretyak E.B. (2007). Postinfectious immunodeficiency and 
autoimmunity: pathogenic and clinical values and implications. Expert Review of 
Clinical Immunology. Vol.3, No.3, (May 2007), pp. 323-331, ISSN 1744-666X 
Miller T.E.; Smith J.W. & Lehmann J.W. Autoimmunity in chronic experimental 
pyelonephritis. J Infect Dis. Vol.122, No.3, (September 1970), pp. 191-195, ISSN 1344-
6304 
Shogenov Z.S.; Akhmedilova K.A. & Tabaksoeva D.A. Features of immunopathogenesis and 
chronization of myocarditis as the basis of immunogenetic diagnostic and 
www.intechopen.com
 Autoimmune Disorders – Pathogenetic Aspects 
 
140 
immunogenetic monitoring protocols development. Russian cardiology journal. 
Vol.6(86), (November 2010), pp. 76-87, ISSN 1560-4071 
Khaitov R.M. & Pinegin B.V. Contemporary conceptions of safeguard of host organism 
against infection. Immunology. Vol.1, (January 2000), pp. 61-64, ISSN 0206-4952 
Bach J.F. Infections and autoimmunity. Rev. Med. Interne. Vol.1, (October 2005), pp. 32-34, 
ISSN 0248-8663 
Sanaev A.O.; Kachkov I.A. & Vinnitskij L.I. (2007). Modern aspects of immunotherapy at 
intracranial infectious inflammatory diseases therapy by example of brain 
abscesses. Allergology and Immunology. Vol.8, No.4, (2007), pp. 384-387, ISSN 1562-
3637 
Vinnitskij L.I. Diagnostic facilities of contemporary immune technologies in surgical clinic. 
(2002) Allergology and Immunology. Vol.3, No.1, (2002), pp. 198-203, ISSN 1562-3637 
Kolesnikov A.P.; Khabarov A.S. & Kozlov V.A. (2001). Diagnostics and differentiated 
treatment of secondary immunodeficiencies. Therapeutic Archives. Vol.73(4), (April 
2001), pp. 55-59, ISSN 0040-3660 
Cherepakhina N.E.; Maksimenko D.M. & Suchkov S.V. (2010). Strategy of immunotherapy 
and immunorehabilitation of chronic relapsing infectious. International Journal on 
Immunorehabilitation. Vol.12, No.2, (May 2010), p. 139, ISSN 1562-3629 
www.intechopen.com
Autoimmune Disorders - Pathogenetic Aspects
Edited by Dr. Clio Mavragani
ISBN 978-953-307-643-0
Hard cover, 508 pages
Publisher InTech
Published online 26, October, 2011
Published in print edition October, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The present edition entitled "Autoimmune disorders - Pathogenetic aspects" ​ aims to present the current
available evidence of etiopathogenetic insights of both systemic and organ specific autoimmune disorders, the
crossover interactions among autoimmunity, cardiovascular morbidity and malignancy as well as novel findings
in the exciting fields of osteoimmunology and immunology of pregnancy.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Natalia Cherepahina, Murat Agirov, Jamilyia Tabaksoeva, Kusum Ahmedilova and Sergey Suchkov (2011).
Postinfectious Autoimmune Syndrome as a Key Factor in Chronization of the Infectious Disease, Autoimmune
Disorders - Pathogenetic Aspects, Dr. Clio Mavragani (Ed.), ISBN: 978-953-307-643-0, InTech, Available from:
http://www.intechopen.com/books/autoimmune-disorders-pathogenetic-aspects/postinfectious-autoimmune-
syndrome-as-a-key-factor-in-chronization-of-the-infectious-disease
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
